The impact of circulating IGF-1 and IGFBP-2 on cardiovascular prognosis in patients with acute coronary syndrome
BackgroundWhile insulin-like growth factor 1 (IGF-1) exerts a cardioprotective effect in the setting of atherosclerosis, insulin-like growth factor binding protein 2 (IGFBP-2) is involved in metabolic syndrome. Although IGF-1 and IGFBP-2 are known to be predictors for mortality in patients with hear...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-03-01
|
| Series: | Frontiers in Cardiovascular Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fcvm.2023.1126093/full |
| _version_ | 1811155458745958400 |
|---|---|
| author | Wei Wang Wei Wang Kang Yu Shou-Yong Zhao De-Gang Mo Jia-Hui Liu Li-Jinn Han Tai Li Heng-Chen Yao Heng-Chen Yao |
| author_facet | Wei Wang Wei Wang Kang Yu Shou-Yong Zhao De-Gang Mo Jia-Hui Liu Li-Jinn Han Tai Li Heng-Chen Yao Heng-Chen Yao |
| author_sort | Wei Wang |
| collection | DOAJ |
| description | BackgroundWhile insulin-like growth factor 1 (IGF-1) exerts a cardioprotective effect in the setting of atherosclerosis, insulin-like growth factor binding protein 2 (IGFBP-2) is involved in metabolic syndrome. Although IGF-1 and IGFBP-2 are known to be predictors for mortality in patients with heart failure, their use in clinic as prognostic biomarkers for acute coronary syndrome (ACS) requires investigation. We evaluated the relationship between IGF-1 and IGFBP-2 levels at admission and the risk of major adverse cardiovascular events (MACEs) in patients with ACS.MethodsA total of 277 ACS patients and 42 healthy controls were included in this prospective cohort study. Plasma samples were obtained and analyzed at admission. Patients were followed for MACEs after hospitalization.ResultsAmong patients who suffered acute myocardial infarction, plasma levels of IGF-1 and IGFBP-2 were lower and higher, respectively, as compared to healthy controls (both p < 0.05). The mean follow-up period was 5.22 (1.0–6.0) months and MACEs incidence was 22.4% (62 of 277 patients). Kaplan–Meier survival analysis revealed that patients with low IGFBP-2 levels had a greater event-free survival rate than patients with high IGFBP-2 levels (p < 0.001). Multivariate Cox proportional hazards analysis revealed IGFBP-2, but not IGF-1, to be a positive predictor of MACEs (hazard ratio 2.412, 95% CI 1.360–4.277; p = 0.003).ConclusionOur findings suggest that high IGFBP-2 levels are associated with the development of MACEs following ACS. Moreover, IGFBP-2 is likely an independent predictive marker of clinical outcomes in ACS. |
| first_indexed | 2024-04-10T04:34:18Z |
| format | Article |
| id | doaj.art-e279545b854d4f409dbcc7b0e953e0f1 |
| institution | Directory Open Access Journal |
| issn | 2297-055X |
| language | English |
| last_indexed | 2024-04-10T04:34:18Z |
| publishDate | 2023-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Cardiovascular Medicine |
| spelling | doaj.art-e279545b854d4f409dbcc7b0e953e0f12023-03-10T04:53:24ZengFrontiers Media S.A.Frontiers in Cardiovascular Medicine2297-055X2023-03-011010.3389/fcvm.2023.11260931126093The impact of circulating IGF-1 and IGFBP-2 on cardiovascular prognosis in patients with acute coronary syndromeWei Wang0Wei Wang1Kang Yu2Shou-Yong Zhao3De-Gang Mo4Jia-Hui Liu5Li-Jinn Han6Tai Li7Heng-Chen Yao8Heng-Chen Yao9Department of Cardiology, Liaocheng People's Hospital, Shandong University, Jinan, ChinaDepartment of Cardiology, Liaocheng People's Hospital Affiliated to Shandong First Medical University, Liaocheng, ChinaDepartment of Laboratory Medicine, Liaocheng People's Hospital Affiliated to Shandong First Medical University, Liaocheng, ChinaDepartment of Laboratory Medicine, Liaocheng People's Hospital Affiliated to Shandong First Medical University, Liaocheng, ChinaDepartment of Cardiology, Liaocheng People's Hospital Affiliated to Shandong First Medical University, Liaocheng, ChinaDepartment of Cardiology, Liaocheng People's Hospital Affiliated to Shandong First Medical University, Liaocheng, ChinaDepartment of Cardiology, Liaocheng People's Hospital Affiliated to Shandong First Medical University, Liaocheng, ChinaDepartment of Nursing, Liaocheng Vocational & Technical College, Liaocheng, ChinaDepartment of Cardiology, Liaocheng People's Hospital, Shandong University, Jinan, ChinaDepartment of Cardiology, Liaocheng People's Hospital Affiliated to Shandong First Medical University, Liaocheng, ChinaBackgroundWhile insulin-like growth factor 1 (IGF-1) exerts a cardioprotective effect in the setting of atherosclerosis, insulin-like growth factor binding protein 2 (IGFBP-2) is involved in metabolic syndrome. Although IGF-1 and IGFBP-2 are known to be predictors for mortality in patients with heart failure, their use in clinic as prognostic biomarkers for acute coronary syndrome (ACS) requires investigation. We evaluated the relationship between IGF-1 and IGFBP-2 levels at admission and the risk of major adverse cardiovascular events (MACEs) in patients with ACS.MethodsA total of 277 ACS patients and 42 healthy controls were included in this prospective cohort study. Plasma samples were obtained and analyzed at admission. Patients were followed for MACEs after hospitalization.ResultsAmong patients who suffered acute myocardial infarction, plasma levels of IGF-1 and IGFBP-2 were lower and higher, respectively, as compared to healthy controls (both p < 0.05). The mean follow-up period was 5.22 (1.0–6.0) months and MACEs incidence was 22.4% (62 of 277 patients). Kaplan–Meier survival analysis revealed that patients with low IGFBP-2 levels had a greater event-free survival rate than patients with high IGFBP-2 levels (p < 0.001). Multivariate Cox proportional hazards analysis revealed IGFBP-2, but not IGF-1, to be a positive predictor of MACEs (hazard ratio 2.412, 95% CI 1.360–4.277; p = 0.003).ConclusionOur findings suggest that high IGFBP-2 levels are associated with the development of MACEs following ACS. Moreover, IGFBP-2 is likely an independent predictive marker of clinical outcomes in ACS.https://www.frontiersin.org/articles/10.3389/fcvm.2023.1126093/fullacute coronary syndromeinsulin-like growth factor-1insulin-like growth factor binding protein 2cardiovascular prognosisIGF-1IGFBP-2 |
| spellingShingle | Wei Wang Wei Wang Kang Yu Shou-Yong Zhao De-Gang Mo Jia-Hui Liu Li-Jinn Han Tai Li Heng-Chen Yao Heng-Chen Yao The impact of circulating IGF-1 and IGFBP-2 on cardiovascular prognosis in patients with acute coronary syndrome Frontiers in Cardiovascular Medicine acute coronary syndrome insulin-like growth factor-1 insulin-like growth factor binding protein 2 cardiovascular prognosis IGF-1 IGFBP-2 |
| title | The impact of circulating IGF-1 and IGFBP-2 on cardiovascular prognosis in patients with acute coronary syndrome |
| title_full | The impact of circulating IGF-1 and IGFBP-2 on cardiovascular prognosis in patients with acute coronary syndrome |
| title_fullStr | The impact of circulating IGF-1 and IGFBP-2 on cardiovascular prognosis in patients with acute coronary syndrome |
| title_full_unstemmed | The impact of circulating IGF-1 and IGFBP-2 on cardiovascular prognosis in patients with acute coronary syndrome |
| title_short | The impact of circulating IGF-1 and IGFBP-2 on cardiovascular prognosis in patients with acute coronary syndrome |
| title_sort | impact of circulating igf 1 and igfbp 2 on cardiovascular prognosis in patients with acute coronary syndrome |
| topic | acute coronary syndrome insulin-like growth factor-1 insulin-like growth factor binding protein 2 cardiovascular prognosis IGF-1 IGFBP-2 |
| url | https://www.frontiersin.org/articles/10.3389/fcvm.2023.1126093/full |
| work_keys_str_mv | AT weiwang theimpactofcirculatingigf1andigfbp2oncardiovascularprognosisinpatientswithacutecoronarysyndrome AT weiwang theimpactofcirculatingigf1andigfbp2oncardiovascularprognosisinpatientswithacutecoronarysyndrome AT kangyu theimpactofcirculatingigf1andigfbp2oncardiovascularprognosisinpatientswithacutecoronarysyndrome AT shouyongzhao theimpactofcirculatingigf1andigfbp2oncardiovascularprognosisinpatientswithacutecoronarysyndrome AT degangmo theimpactofcirculatingigf1andigfbp2oncardiovascularprognosisinpatientswithacutecoronarysyndrome AT jiahuiliu theimpactofcirculatingigf1andigfbp2oncardiovascularprognosisinpatientswithacutecoronarysyndrome AT lijinnhan theimpactofcirculatingigf1andigfbp2oncardiovascularprognosisinpatientswithacutecoronarysyndrome AT taili theimpactofcirculatingigf1andigfbp2oncardiovascularprognosisinpatientswithacutecoronarysyndrome AT hengchenyao theimpactofcirculatingigf1andigfbp2oncardiovascularprognosisinpatientswithacutecoronarysyndrome AT hengchenyao theimpactofcirculatingigf1andigfbp2oncardiovascularprognosisinpatientswithacutecoronarysyndrome AT weiwang impactofcirculatingigf1andigfbp2oncardiovascularprognosisinpatientswithacutecoronarysyndrome AT weiwang impactofcirculatingigf1andigfbp2oncardiovascularprognosisinpatientswithacutecoronarysyndrome AT kangyu impactofcirculatingigf1andigfbp2oncardiovascularprognosisinpatientswithacutecoronarysyndrome AT shouyongzhao impactofcirculatingigf1andigfbp2oncardiovascularprognosisinpatientswithacutecoronarysyndrome AT degangmo impactofcirculatingigf1andigfbp2oncardiovascularprognosisinpatientswithacutecoronarysyndrome AT jiahuiliu impactofcirculatingigf1andigfbp2oncardiovascularprognosisinpatientswithacutecoronarysyndrome AT lijinnhan impactofcirculatingigf1andigfbp2oncardiovascularprognosisinpatientswithacutecoronarysyndrome AT taili impactofcirculatingigf1andigfbp2oncardiovascularprognosisinpatientswithacutecoronarysyndrome AT hengchenyao impactofcirculatingigf1andigfbp2oncardiovascularprognosisinpatientswithacutecoronarysyndrome AT hengchenyao impactofcirculatingigf1andigfbp2oncardiovascularprognosisinpatientswithacutecoronarysyndrome |